PetMed Express Q4 net loss widens to $5.0M; FY net loss $7.5M vs prior year profit

PETMED EXPRESS INC

Q4 net sales $66.5M (+6.6% YoY) driven by PetCareRx acquisition; legacy PetMeds sales declined.
Q4 net loss $5.0M ($0.25 diluted EPS) vs loss $0.2M ($0.01) in prior year quarter.
FY 2024 net loss $7.5M ($0.37 diluted EPS) vs net income $5.1M ($0.25) in FY 2023.
Adjusted EBITDA Q4 $0.5M (from $3.6M); FY $8.2M (from $19.8M) as G&A and marketing rose.
CEO cites challenging macro environment and new Order Management System slowdown in Q4.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.